The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R/R DLBCL
Gareth Gregory, MBBS, PhD, FRACP, FRCPA, Monash University, Monash Health, Melbourne, Australia, discusses the Phase III STARGLO trial (NCT04408638), evaluating glofitamab in combination with gemcitabine and oxaliplatin vs rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The primary endpoint of the trial was met, with the combination including glofitamab having a significant clinical benefit in overall survival (OS) and a manageable toxicity profile. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: Merck, Gilead, BMS, Roche, Novartis, Prelude Therapeutics, Clinigen; Research Funding (to Institute): Merck, BeiGene, Janssen.
